EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Perils and progress in epilepsy surgery utilization: Twenty‐five years later

Dario J Englot iD

Epilepsia · 2026-11 · 67 (11) · 5563-5576

DOI: 10.1002/epi.70419 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Epilepsia, online erschienen am 18.08.2026. Verfasst von Dario J Englot. Beteiligte Einrichtung: Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Neurosurgical Procedures, Epilepsy. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

More than 25 years have passed since the first randomized controlled trial (RCT) established that surgery is superior to continued anti‐seizure medication (ASM) for drug‐resistant temporal lobe epilepsy, and nearly as long since a joint practice parameter urged that appropriate surgical candidates be referred to a specialized center for evaluation—guidance that subsequent consensus has since broadened to all patients with drug‐resistant epilepsy. Despite Class I evidence and durable guidelines, epilepsy surgery remains one of the most underutilized effective interventions in medicine: fewer than 1% of potentially eligible patients are referred, and those who are referred reach a center on average two decades after seizure onset. This critical review, framed primarily around U.S. data and supplemented by a dedicated assessment of the global picture, examines the scope and burden of drug‐resistant epilepsy (DRE), the foundational evidence and guideline history, and the magnitude, patterns, and causes of persistent underutilization, including a distinct discussion of pediatric care and of disparities by race, insurance, and geography. We then turn to grounds for optimism. Surgical candidacy has materially expanded through minimally invasive approaches to both monitoring (stereo‐electroencephalography) and treatment (laser interstitial thermal therapy and neuromodulation), and indications have broadened to include selected generalized and multifocal epilepsies through thalamic neuromodulation. Contemporary International League Against Epilepsy (ILAE) recommendations go further still, extending referral even to selected patients who are seizure‐free on medication but harbor a surgically accessible lesion. We also raise a counterbalancing concern: the welcome diffusion of minimally invasive options should not eclipse resective and disconnective surgery, which remain the only potentially curative options validated by RCTs. We conclude that, 25 years on, underutilization persists as a major and partly remediable problem, and we offer recommendations for closing the surgical gap.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyNeurosurgical ProceduresEpilepsyHumans

Stichwörter der Autor:innen

drug‐resistant epilepsyepilepsy surgeryhealth care disparitieslaser interstitial thermal therapyneuromodulationreferral

Autor:innen und Institutionen

  • Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Dario J Englot

Zitieren

APA

Englot, D. J. (2026). Perils and progress in epilepsy surgery utilization: Twenty‐five years later. Epilepsia, 67(11), 5563-5576. https://doi.org/10.1002/epi.70419

Vancouver

Englot DJ. Perils and progress in epilepsy surgery utilization: Twenty‐five years later. Epilepsia. 2026;67(11):5563-5576. doi:10.1002/epi.70419

BibTeX
@article{Englot2026,
  author = {Englot, Dario J},
  title = {Perils and progress in epilepsy surgery utilization: Twenty‐five years later},
  journal = {Epilepsia},
  year = {2026},
  volume = {67},
  number = {11},
  pages = {5563--5576},
  doi = {10.1002/epi.70419}
}
Kostenlos starten →